A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.

Neeta Somaiah,Anthony Paul Conley,Heather Lin,Behrang Amini,Sharjeel H. Sabir,Dejka M. Araujo,Robert S. Benjamin,J. Andrew Livingston,Shreyaskumar Patel,Ravin Ratan,Vinod Ravi,Maria Alejandra Zarzour,Wei Lien Wang,Taylor Tate,Christina L. Roland,Najat C. Daw,Andrew Futreal,Alexander J. Lazar,Ignacio I. Wistuba,Patrick Hwu

A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.

2020

11509Background: The combination of durvalumab (D), (anti- PD-L1) and tremelimumab (T), (anti-CTLA-4), was evaluated to determine activity in specific sarcoma subtypes (NCT02815995). We report fina...

Keywords:

Tremelimumab
Oncology
Durvalumab
Internal medicine
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations